Bradley Duffy

Array ( [id] => 18842742 [patent_doc_number] => 20230405146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => Antibody-conjugated nanoparticles [patent_app_type] => utility [patent_app_number] => 18/251988 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18251988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563222 [patent_doc_number] => 20220127371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/518123 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17518123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641961 [patent_doc_number] => 20220169699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => PD-1-CD28 FUSION PROTEINS AND THEIR USE IN MEDICINE [patent_app_type] => utility [patent_app_number] => 17/515250 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17515250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20459441 [patent_doc_number] => 20260008864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => BISPECIFIC ANTI-CD38-CD3 BINDERS [patent_app_type] => utility [patent_app_number] => 18/250918 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749673 [patent_doc_number] => 20220227877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/507895 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786127 [patent_doc_number] => 20230374140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/247864 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20562935 [patent_doc_number] => 12565536 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-03 [patent_title] => Method for generating avid-binding multispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/488698 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 12191 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 283 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20715604 [patent_doc_number] => 12630843 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Polynucleotide for physiological expression in T-cells [patent_app_type] => utility [patent_app_number] => 18/246173 [patent_app_country] => US [patent_app_date] => 2021-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 3 [patent_no_of_words] => 5725 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704619 [patent_doc_number] => 20220204625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Combination Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/479930 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693989 [patent_doc_number] => 20230324392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS [patent_app_type] => utility [patent_app_number] => 18/043527 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690969 [patent_doc_number] => 20230321144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => MODIFIED IMMUNE CELLS FOR FIBROSIS AND INFLAMMATION [patent_app_type] => utility [patent_app_number] => 18/023060 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311816 [patent_doc_number] => 12037619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Angiotensin-converting enzyme 2 (ACE2) immunoadhesin microbody [patent_app_type] => utility [patent_app_number] => 17/405104 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 17 [patent_no_of_words] => 13386 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20921844 [patent_doc_number] => 12716899 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-25 [patent_title] => Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels [patent_app_type] => utility [patent_app_number] => 17/393267 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 38 [patent_no_of_words] => 9876 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264153 [patent_doc_number] => 12435129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Anti-Ab antibodies [patent_app_type] => utility [patent_app_number] => 17/383765 [patent_app_country] => US [patent_app_date] => 2021-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 49 [patent_no_of_words] => 19170 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368368 [patent_doc_number] => 20220023420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => FUSION CONSTRUCTS AND METHODS OF USING THEREOF [patent_app_type] => utility [patent_app_number] => 17/305577 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18550783 [patent_doc_number] => 20230248783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES [patent_app_type] => utility [patent_app_number] => 18/012498 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7650 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399635 [patent_doc_number] => 20220041725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Combination Therapy for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/351724 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20179509 [patent_doc_number] => 20250263467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION [patent_app_type] => utility [patent_app_number] => 18/001583 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -88 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297854 [patent_doc_number] => 20210393693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/342518 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79137 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667564 [patent_doc_number] => 12180292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => CD70 binding molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/328118 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 57 [patent_no_of_words] => 38265 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328118 [rel_patent_id] =>[rel_patent_doc_number] =>)